R&D Cutbacks Unlikely Under Any Medicare Plan, AARP's Smith Says
Pharmaceutical companies are not likely to scale back R&D, even if a Medicare drug benefit affects the profitability of manufacturers, AARP Director for Health Issues Patricia Smith suggested during an Alliance for Health Reform briefing April 20 in Washington, D.C.
You may also be interested in...
The $300 bil. budget set-aside for a Medicare prescription drug benefit may not be sufficient to cover low-income provisions of drug benefit proposals, AARP maintains.
Newly released Medicare Part D data sheds light on the sales hit that branded pharmaceutical manufacturers will face when the coverage gap discount program gets under way in 2011